Prothrombin complex concentrate for oral factor Xa inhibitor-associated intracerebral hemorrhage
Research article published in Research and practice in thrombosis and haemostasis (2026)
Abstract
BACKGROUND: Factor Xa inhibitor-associated intracerebral hemorrhage (ICH) requires rapid anticoagulation reversal. Although andexanet alfa, a specific FXaI antidote, demonstrated efficacy in andexenet alfa for acute intracerebral hemorrhage (ANNEXA-I) trial, it was associated with a high thromboembolic rate. Consequently, 4-factor prothrombin complex concentrate (4F-PCC) is widely used, though real-world data remain limited. OBJECTIVE: To assess the hemostatic effectiveness and safety of 4F-PCC for reversal of oral factor Xa inhibitors in patients with acute intracerebral hemorrhage. METHODS: We conducted a single-center, retrospective observational study of consecutive patients with FXaI-associated ICH treated with 4F-PCC between January 2017 and May 2025. The primary endpoint was hemostatic efficacy according to ANNEXA-I criteria: hematoma expansion < 35%, National Institutes of Health Stroke Scale (NIHSS) score increase of <7 points, and absence of rescue therapy within 12 hours. The secondary endpoint was a stable neurological status (no worsening of the NIHSS score) at 48 hours. Safety outcomes included 30-day thromboembolic events and mortality. RESULTS: Fifty-two patients (median age, 81 years; IQR, 75-87; 61.5% male) were included. Apixaban was the most frequent FXaI (86.6%), with atrial fibrillation as the main indication (94.3%). The median baseline hematoma volume was 5.45 mL (IQR, 2-21), and the NIHSS score was 4.5 (IQR, 1-6). The primary endpoint was achieved in 39 patients (75.0%; 95% CI, 61.1%-86.0%). Stable neurological status at 48 hours occurred in 37 patients (71.2%; 95% CI, 56.9%-82.9%). One thromboembolic event (deep vein thrombosis) occurred (1.9%; 95% CI, 0.0%-10.3%), and 12 patients (23.1%; 95% CI, 12.5%-36.8%) died within 30 days. CONCLUSION: 4F-PCC achieved high hemostatic efficacy and low thromboembolic risk in FXaI-associated ICH. Mortality was comparable to ANNEXA-I, but thrombotic events were markedly lower, supporting current guideline recommendations for 4F-PCC use in this setting.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
In 52 patients with factor Xa inhibitor-associated intracerebral hemorrhage, 4F-PCC achieved hemostatic efficacy in 75% by ANNEXA-I criteria, with one thromboembolic event (1.9%) and 23.1% 30-day mortality, supporting guideline-endorsed 4F-PCC use in this setting.
Context
This single-center retrospective study of 52 patients evaluated 4-factor prothrombin complex concentrate (4F-PCC) for reversing factor-Xa-inhibitor-associated intracerebral hemorrhage, reporting hemostatic efficacy by ANNEXA-I criteria in 75.0% of patients with one thromboembolic event (1.9%) and 23.1% 30-day mortality. It illustrates the central clinical tension -- bleeding versus clotting -- that defines all anticoagulant therapy, including the medicinal-leech secretome, and highlights that any potent anticoagulant raises the parallel problem of safe reversal. This is a small, single-center, retrospective observational study of a pharmaceutical reversal agent in pharmaceutical Xa-inhibitor bleeding; it involves no leeches or hirudotherapy.
Citation
Reference (Vancouver style)
Shamiea M, Sbehi H, Rashed NA, Kashua A, Fanadka F, Rabina E, et al. Prothrombin complex concentrate for oral factor Xa inhibitor-associated intracerebral hemorrhage. Res Pract Thromb Haemost. 2026;10(1):103361. doi:10.1016/j.rpth.2026.103361. PMID: 41695666
Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.
Added to ASH library: May 28, 2026 · Site last updated: November 1, 2026